...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: NKF meeting

The message from the site is that the trial is not yet completed. But as Bear said, this could be because they have been too busy or too lazy to get it up to date. Let's hope it's the former.

An open label follow-up extension would be easier and cheaper than a bolt-on if the FDA would accept it.

Share
New Message
Please login to post a reply